RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Alvogen,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Amneal Pharmaceuticals, Inc,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Aurobindo Pharma USA, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Aytu BioPharma, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Camber Pharmaceuticals, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Epic Pharma, LLC,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Granules Pharmaceuticals, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Lannett Company, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Prasco,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Rhodes Pharmaceuticals,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Sandoz Pharmaceuticals,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Shire PLC/Takeda Pharmaceuticals,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Solco Healthcare US, LLC,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear SpecGX LLC,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Sun Pharmaceutical Industries Ltd,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Sunrise Pharmaceutical, Inc,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Tris Pharma, Inc.,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear Teva Pharmaceuticals,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

August 3, 2023

Dear US Pharma Windlas LLC,

Oregonians and the community pharmacies they count on for local, dependable service regularly tell me of their difficulty securing access to much-needed medications for attention deficit hyperactivity disorder (ADHD), particularly the generic versions of these medications. I've engaged with federal agencies on how they are working with manufacturers to address this troubling shortage.

The Drug Enforcement Agency (DEA) informed me that it told all manufacturers in a May 18 letter about their concerns regarding the supply of amphetamine and amphetamine products. In that letter, the DEA notes that in 2022, manufacturers sold about 70 percent of their allotted quota for ADHD products for the year, with 1 billion dosage units that were authorized but not shipped or sold. A few months into the 2023 calendar year, manufacturers also had allotted quota they had not fully used. The agency added in the letter that it stood ready to "expeditiously review and adjudicate individual applications under the current authorized quota levels for amphetamine, in accordance with DEA regulations." However, shortages persist.

On August 1, the U.S. Food and Drug Administration (FDA) and the DEA released a joint statement at my request providing an update on the shortage of prescription stimulants hurting Oregonians and all Americans needing these crucial medications. The statement mentioned the 2022 shortfall and, concerningly, added that this year showed a similar trend - that manufacturers are not using their entire quotas. Both agencies called on manufacturers to either increase their manufacturing of these medications or relinquish their remaining allotment for the DEA to redistribute to manufacturers that wished to produce more than their allotted quota.

DEA tells me the May 18 letter intended to spur manufacturers with excess production capacity to increase their production. Yet as of August 1, according to the agencies' analysis that has not happened and manufacturers are yet again on track to fall ONE BILLION doses below quota, even as patients struggle to obtain medication that their professional health care providers have legally prescribed.

This state of affairs is unacceptable and can be reversed.

The following actions are urgently needed: companies with spare quota allotments should relinquish them to the DEA so the DEA can approve applications from companies that have requested an increase; companies with excess production capacity that have met their quota allotment should apply for an increase; and manufacturers should sufficiently report voluntary and required information on their

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION

production so the agencies have a complete understanding of how the shortage is being resolved and potential future shortages.

Those diagnosed with ADHD and their families, health care professionals, and policymakers are counting on industry and regulators to work closely together to both address the immediate crisis and consider long-term solutions to prevent and mitigate future shortages. Pharmacy shopping or half-filled prescriptions are not helpful, but more and more they are becoming the norm as people seek treatment for recognized medical conditions.

I respectfully request your answers to the following questions about your manufacturing plans by Thursday, August 10th, 2023:

1. Have you met or do you expect to meet your allotted quota amount to produce amphetamine products for 2023?

2. If you will not meet the quota amount, how much of the remainder do you expect to use?

3. Have you or will you commit to relinquishing quota you will not use to the DEA?
    - If not, please explain the reasoning.

4. If you have or will meet the quota, do you have excess production capacity and have you requested permission from the DEA to increase your quota allotment?
    - If you have excess production capacity, are there other obstacles to requesting a quota allotment increase or using that capacity?

I urge you to take appropriate action outlined by the DEA and promptly respond to this letter. Your actions and response will provide the answers Americans and their health providers need to keep ADHD medications available to patients when they are lawfully prescribed.

Sincerely,

RON WYDEN
OREGON

CHAIRMAN OF COMMITTEE ON
FINANCE

221 DIRKSEN SENATE OFFICE BUILDING
WASHINGTON, DC 20510
(202) 224–5244

United States Senate
WASHINGTON, DC 20510–3703

COMMITTEES:
COMMITTEE ON FINANCE
COMMITTEE ON THE BUDGET
COMMITTEE ON ENERGY AND NATURAL RESOURCES
SELECT COMMITTEE ON INTELLIGENCE
JOINT COMMITTEE ON TAXATION



Ron Wyden
United States Senator

911 NE 11TH AVENUE
SUITE 630
PORTLAND, OR 97232
(503) 326–7525

405 EAST 8TH AVE
SUITE 2020
EUGENE, OR 97401
(541) 431–0229

SAC ANNEX BUILDING
105 FIR ST
SUITE 201
LA GRANDE, OR 97850
(541) 962–7691

U.S. COURTHOUSE
310 WEST 6TH ST
ROOM 118
MEDFORD, OR 97501
(541) 858–5122

THE JAMISON BUILDING
131 NW HAWTHORNE AVE
SUITE 107
BEND, OR 97701
(541) 330–9142

707 13TH ST, SE
SUITE 285
SALEM, OR 97301
(503) 589–4555

HTTPS://WYDEN.SENATE.GOV